BRPI1013361A2 - método para evitar e tratar hipermeabilidade. - Google Patents

método para evitar e tratar hipermeabilidade.

Info

Publication number
BRPI1013361A2
BRPI1013361A2 BRPI1013361A BRPI1013361A BRPI1013361A2 BR PI1013361 A2 BRPI1013361 A2 BR PI1013361A2 BR PI1013361 A BRPI1013361 A BR PI1013361A BR PI1013361 A BRPI1013361 A BR PI1013361A BR PI1013361 A2 BRPI1013361 A2 BR PI1013361A2
Authority
BR
Brazil
Prior art keywords
hypermeability
treat
prevent
treat hypermeability
Prior art date
Application number
BRPI1013361A
Other languages
English (en)
Inventor
Berhard Fisher
Rudolf Lucas
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of BRPI1013361A2 publication Critical patent/BRPI1013361A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1013361A 2009-03-05 2010-03-05 método para evitar e tratar hipermeabilidade. BRPI1013361A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0035909A AT507953B1 (de) 2009-03-05 2009-03-05 Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
PCT/AT2010/000056 WO2010099556A1 (de) 2009-03-05 2010-03-05 Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität

Publications (1)

Publication Number Publication Date
BRPI1013361A2 true BRPI1013361A2 (pt) 2016-03-29

Family

ID=42115985

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013361A BRPI1013361A2 (pt) 2009-03-05 2010-03-05 método para evitar e tratar hipermeabilidade.

Country Status (16)

Country Link
US (3) US20110319316A1 (pt)
EP (1) EP2403519B1 (pt)
JP (1) JP5687213B2 (pt)
KR (1) KR101650051B1 (pt)
CN (1) CN102355906A (pt)
AT (1) AT507953B1 (pt)
AU (1) AU2010220800B2 (pt)
BR (1) BRPI1013361A2 (pt)
CA (1) CA2752890C (pt)
DK (1) DK2403519T3 (pt)
ES (1) ES2657445T3 (pt)
MX (1) MX2011008961A (pt)
NO (1) NO2403519T3 (pt)
RU (1) RU2011140057A (pt)
TW (1) TWI466679B (pt)
WO (1) WO2010099556A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
ES2542227T3 (es) * 2010-06-21 2015-08-03 Apeptico Forschung Und Entwicklung Gmbh Tratamiento de complicaciones vasculares de diabetes
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
ES2813379T3 (es) * 2013-04-23 2021-03-23 Apeptico Forschung & Entwicklung Gmbh Tratamiento extracorporal del pulmón con un péptido cíclico de formula x1-gqretpegaeakpwy-x2
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
EP2988768B1 (de) * 2013-04-23 2021-03-31 APEPTICO Forschung und Entwicklung GmbH Lyophilisat enthaltend ein zyklisches peptid der formel x1-gqretpegaeakpwy-x2 zur behandlung pulmonarer ödeme
US20170014472A1 (en) * 2014-03-04 2017-01-19 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
EP3062772B1 (en) * 2014-03-18 2018-01-24 APEPTICO Forschung und Entwicklung GmbH Dry-powder peptide medicament
AU2017415108A1 (en) * 2017-05-26 2019-12-19 Viramatix Sdn Bhd Peptides and uses therefor as antiviral agents
US20250241978A1 (en) * 2020-05-08 2025-07-31 Apeptico Forschung Und Entwicklung Gmbh Peptide for prevention or treatment of covid-19

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509604A (en) * 1998-08-14 2003-05-30 Innogenetics N TNF-derived peptides for use in treating oedema
CZ20013580A3 (cs) * 1999-04-06 2002-03-13 Knoll Gmbh Substituované 1,4-dihydroindeno[1,2-c]pyrazoly jako inhibitory tyrosin kinázy
FR2825592B1 (fr) 2001-06-08 2003-08-08 Oreal Dispositif pour l'application en meches d'un produit capillaire, et procede de traitement capillaire
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1781323B1 (en) * 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
WO2007033216A2 (en) * 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität

Also Published As

Publication number Publication date
CN102355906A (zh) 2012-02-15
CA2752890C (en) 2018-02-27
AT507953B1 (de) 2011-02-15
DK2403519T3 (en) 2018-01-22
EP2403519A1 (de) 2012-01-11
KR101650051B1 (ko) 2016-08-22
CA2752890A1 (en) 2010-09-10
NO2403519T3 (pt) 2018-04-14
JP5687213B2 (ja) 2015-03-18
WO2010099556A8 (de) 2010-11-11
RU2011140057A (ru) 2013-04-10
AT507953A1 (de) 2010-09-15
US20140364358A1 (en) 2014-12-11
US20110319316A1 (en) 2011-12-29
WO2010099556A1 (de) 2010-09-10
EP2403519B1 (de) 2017-11-15
TWI466679B (zh) 2015-01-01
MX2011008961A (es) 2011-11-18
AU2010220800A1 (en) 2011-09-15
JP2012519188A (ja) 2012-08-23
US11639368B2 (en) 2023-05-02
KR20110122836A (ko) 2011-11-11
ES2657445T3 (es) 2018-03-05
US20190040105A1 (en) 2019-02-07
TW201041589A (en) 2010-12-01
AU2010220800B2 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
BRPI1013361A2 (pt) método para evitar e tratar hipermeabilidade.
BR112012020425A2 (pt) dispositivo e método para tratamento de água
BR112013010725A2 (pt) método, e, composição
BR112012000882A2 (pt) Preparação cosmética capilar e método para aplicação.
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BR112013013584A2 (pt) endoscópio, e, método
BR112012015322A2 (pt) propante e método para formar o propante
BR112013015870A2 (pt) método para o tratamento de biomassa e sistema
BR112012000171A2 (pt) composição lubrificante, e, método
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
BRPI1013878A2 (pt) método para tratar distúrbios metabólicos, e, composto
BRPI1015233A2 (pt) métodos para tratar ou prevenir a fadiga
BR112012027159A2 (pt) estrutura e método
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0919127A2 (pt) métodos para tratamento de água
BRPI1011226A2 (pt) métodos para tratar condições relacionadas ao cabelo
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BR112014015551A2 (pt) método para tratar lama e método para desidratação de lama
BRPI1008484A2 (pt) codificador, decodificador e método para os mesmos
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1008253A2 (pt) Metoso para tratar biomassa
BRPI0924019A2 (pt) método de fermentação e aparelhos adaptados para o método
BR112012008229A2 (pt) método, e aparelho
BR112013022306A2 (pt) método, e, composição

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]